MDASI Chronic Myeloid Leukemia Module
The MD Anderson Symptom Inventory for chronic myeloid leukemia (MDASI-CML) is a disease-specific MDASI module. Use the MDASI-CML to assess the severity of symptoms experienced by patients with chronic myeloid leukemia and the interference with daily living caused by these symptoms.
Along with the core MDASI’s 13 symptom items and 6 interference items, the MDASI-CML also assesses 7 symptoms specific to chronic myeloid leukemia.
| Core MDASI Symptoms | CML Symptoms | MDASI Interference |
|---|---|---|
| Pain | Diarrhea (loose stools) | Relations with other people |
| Fatigue | Swelling | Enjoyment of life |
| Nausea | Rash or skin changes | Mood |
| Disturbed sleep | Muscle soreness or cramping | Walking |
| Distress (feeling upset) | Bruising or bleeding easily | Activity |
| Shortness of breath | Malaise | Work (including housework) |
| Difficulty remembering | Headache | |
| Lack of appetite | ||
| Drowsiness | ||
| Dry mouth | ||
| Sadness | ||
| Vomiting | ||
| Numbness/tingling |
Order the MDASI-CML
Use our convenient online form to order the MDASI-CML for use in your clinical research, clinical practice, funded and non-funded academic research, commercial research, or reproduction in educational materials or other publications.
MDASI-CML Features
- Purpose: To assess the severity of multiple chronic myeloid leukemia-related symptoms and the impact of these symptoms on daily functioning
- Population: Patients with symptoms caused by chronic myeloid leukemia and its treatment
- Assessment areas: Severity of multiple symptoms and the impact of symptoms on daily functioning during the last 24 hours
- Method: Self-report or interview with research staff; paper-and-pencil or electronic data entry*
- Time required: Five minutes or less
- Scoring: Please see the MDASI User Guide
- Reliability: Cronbach alpha reliability ranges from 0.91 to 0.95
*Electronic data capture offers several benefits:
- Allows symptom monitoring when the patient is away from the hospital
- Is convenient for patients, who can choose web access, personalized patient portals, or smartphones to access questionnaires
- Minimizes missing data, especially in longitudinal studies
- Provides accurate, real-time symptom data at expected time points
- Generates immediate feedback, potentially allowing caregivers to address severe symptoms more effectively
MDASI-CML Language Versions
Click on a linked language to view a sample in PDF format.
Don't see a language you need? Contact us at symptomresearch@mdanderson.org.
| Psychometrically and Linguistically Validated | Linguistically Validated |
|---|---|
| English | Arabic |
| Bulgarian | |
| Chinese (Simplified) | |
| Chinese (Traditional) | |
| Czech | |
| Danish | |
| Dutch | |
| Finnish | |
| French | |
| German | |
| Greek | |
| Hebrew | |
| Hungarian | |
| Italian | |
| Japanese | |
| Korean | |
| Malay (in process) | |
| Polish | |
| Portuguese (Brazil) | |
| Portuguese (Portugal) | |
| Russian | |
| Serbian | |
| Spanish | |
| Swedish | |
| Thai |
MDASI User Guide
In response to the US Food and Drug Administration's 2009 guidance for the pharmaceutical industry on the use of patient-reported outcomes measures in medical product development to support labeling claims, we have prepared a MDASI User Guide to document the development and psychometric properties of the MDASI and its modules, including the MDASI-CML. The User Guide addresses the recommendations in the FDA guidance and establishes the MDASI's adequacy as a measure to support medical product claims.
Selected MDASI-CML References
Validation
Williams LA, Garcia-Gonzalez A, Ault P, et al. Measuring the symptom burden associated with the treatment of chronic myeloid leukemia. Blood 122(5):641-647, 2013.
Williams LA, Garcia-Gonzalez A, Ault P, et al. A new symptom measure in chronic myeloid leukemia [abstract]. American Society of Clinical Oncology 47th Annual Meeting, Chicago IL, Jun 3-7, 2011. J Clin Oncol 29(15 Suppl), 2011; e19545.
Williams LA, Cortes JE, Ault P, Garcia-Gonzalez A, Williams JL, Cleeland CS. Including patient input in patient-reported outcome instrument development: examples from the MDASI-CML [abstract]. American Society of Hematology 2010 Annual Meeting, Orlando FL, Dec 4-7, 2010. Blood 116(21): 1065, 2010; 2573.
Cleeland CS, Mendoza TR, Wang XS, et al. Assessing symptom distress in cancer: the M. D. Anderson Symptom Inventory. Cancer 89:1634-1646, 2000.
Clinical Application
Réa D, Boquimpani C, Mauro MJ, et al. Health-related quality of life of patients with resistant/intolerant chronic phase chronic myeloid leukemia treated with asciminib or bosutinib in the phase 3 ASCEMBL trial. Leukemia 37(5):1060-1067, 2023.
Schoenbeck KL, Flynn KE. Health-related quality of life of patients with chronic myeloid leukemia as measured by patient-reported outcomes: current state and future directions. Curr Hematol Malig Rep 16(6):491-499, 2021.
Bostan H, Toptas T, Tanrikulu FP, et al. Quality of life and symptom burden with first- and second-generation tyrosine kinase Inhibitors in patients with chronic-phase chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk 20(12):836-842, 2020.
Zulbaran-Rojas A, Lin HK, Shi Q, et al. A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors. Cancer Med 7(11):5457-5469, 2018.
Williams LA, Ault P, Garcia-Gonzalez A, et al. Relationship of patient-reported symptoms to daily functioning in chronic myeloid leukemia [abstract]. American Society of Hematology 54th Annual Meeting and Exposition, Atlanta GA, Dec 8-11, 2012. Blood 118(21): 2012; 4260.
Williams LA, Jacobsen PB, Sailors MH, et al. Symptoms in chronic myeloid leukemia survivors on tyrosine kinase inhibitor therapy at two cancer centers [abstract]. Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) 2012 International Symposium on Supportive Care in Cancer, New York NY, Jun 28-30, 2012. Support Care Cancer 20(Suppl 1): S240, 2012; 1003.
Garcia-Gonzalez A, Ault P, Williams LA, et al. Interactive voice response system compliance in chronic myeloid leukemia population [abstract]. American Society of Clinical Oncology 48th Annual Meeting, Chicago IL, Jun 1-5, 2012; e19589.
Williams LA, Ault PS, Garcia-Gonzalez A, et al. Identifying high symptom burden in patients with chronic myeloid leukemia on tyrosine kinase inhibitor therapy [abstract]. American Society of Hematology 53rd Annual Meeting and Exposition, San Diego CA, Dec 10-13, 2011. Blood 118(21): 1356, 2011; 3138.
Every MDASI module contains:
all 13 core MDASI symptoms...
pain, fatigue, nausea, disturbed sleep, distress, shortness of breath, difficulty remembering, lack of appetite, drowsiness, dry mouth, sadness, vomiting, numbness/tingling
...and all 6 MDASI interference items
general activity, mood, work, relations with others, walking, enjoyment of life
In our studies, a third of patients with CML reported having moderate-to-severe symptoms.
The MDASI-CML is a valid and reliable questionnaire that can help researchers and clinicians identify and assess these symptoms.
Loretta A. Williams, Ph.D., RN, AOCN
Associate Professor, Symptom Research